KK 3910
Alternative Names: KK-3910Latest Information Update: 31 Mar 2025
At a glance
- Originator Kyowa Kirin
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Essential hypertension
Most Recent Events
- 19 Feb 2025 Preclinical trials in Essential hypertension in Japan (SC) (NCT06823947)
- 14 Feb 2025 Kyowa Kirin plans phase-I trial for Essential hypertension in March 2025 (SC, injection) (NCT06823947)